Edition:
United States

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

19.60EUR
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
€19.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
28,587
52-wk High
€23.88
52-wk Low
€12.96

Select another date:

Tue, Nov 14 2017

BRIEF-Biotest 9-mth revenue at EUR 377.8 mln

* DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017

UPDATE 1-Takeover of plasma firm Biotest by China's Creat hits wall in U.S.

* Biotest shares drop 12 percent to 7-month low (Adds share price, background)

China's Creat suffers setback in Biotest deal on U.S. scrutiny

FRANKFURT Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest , the German blood plasma products maker said, sending its shares sharply lower.

BRIEF-Biotest: Tiancheng withdrawal of application of transaction from CFIUS and refiling

* ‍TENDER OFFER BY TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG​

BRIEF-Curetis partners with Biotest to support academic PEPPER Pentaglobin Peritonitis trial

* CURETIS PARTNERS WITH BIOTEST TO SUPPORT ACADEMIC PEPPER PENTAGLOBIN® PERITONITIS TRIAL WITH UNYVERO IAI APPLICATION

BRIEF-Biotest H1 result swings to loss of 17.8 million euros

* H1 REVENUE FROM CONTINUING OPERATIONS FELL 11 PERCENT TO 247.1 MILLION EUR

BRIEF-Biotest takes over plasma supplier Cara Plasma s.r.o.

* ‍BIOTEST TAKES OVER CARA PLASMA S.R.O. WITH ONE PLASMA COLLECTION CENTRE IN CZECH REPUBLIC​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Tiancheng Pharmaceutical Holdings: offer for Biotest accepted for 89.9 pct of share capital‍​‍​

* TIANCHENG (GERMANY) PHARMACEUTICAL HOLDINGS AG - AFTER END OF ADDITIONAL ACCEPTANCE PERIOD OFFER ACCEPTED FOR 17.8 MILLION BIOTEST SHARES, THAT IS 89.9% SHARE CAPITAL‍​‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biotest reaches 2nd milestone in expansion project

* DGAP-NEWS: BIOTEST AG: BIOTEST REACHES 2ND MILESTONE IN BIOTEST NEXT LEVEL EXPANSION PROJECT

BRIEF-Tiancheng Pharmaceutical Holdings: additional acceptance period for Biotest tender offer

* START OF MANDATORY ADDITIONAL ACCEPTANCE PERIOD FOR BIOTEST AG TENDER OFFER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: